Research programme: metabolic disorder therapeutics - EastGate Biotech

Drug Profile

Research programme: metabolic disorder therapeutics - EastGate Biotech

Alternative Names: Intraoral insulin - EastGate Biotech

Latest Information Update: 06 Feb 2015

Price : $50

At a glance

  • Originator EastGate Acquisitions
  • Developer EastGate Biotech
  • Class Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Diabetes mellitus
  • Research Metabolic disorders; Obesity

Most Recent Events

  • 03 Feb 2015 East Gate files for patent protection with US PTO for intraoral insulin formulation
  • 15 Dec 2014 EastGate Biotech is now EastGate Acquisitions
  • 18 Aug 2014 Early research in Obesity in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top